Novo Holdings: Controlling Shareholder of Novo Nordisk, Europe's Most Valuable Company - With CEO, Kasim Kutay

episode

Previously titled “142: Novo Holdings: Controlling Shareholder of Novo Nordisk, Europe's Most Valuable Company - With CEO, Kasim Kutay” — renamed by the publisher on Aug 6, 2026

Money Maze Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Tom Cruise Pulled His Own Tooth Out w/ Rob Lowe | 2 Bears, 1 Cave 1h 52m · 28 Sep 2026 · 2 Bears, 1 Cave with Tom Segura & Bert Kreischer

Key Saudi Arabian Pipeline Starts Exports, Nvidia’s AI System, More 7 min · 28 Sep 2026 · Bloomberg News Now

Bonus Episode: Caitríona Balfe on Sense & Sensibility 24 min · 28 Sep 2026 · The Women's Podcast

Mister Petty 2h 51m · 28 Sep 2026 · UNspoiled! The Dresden Files

The Day You Stop Playing It Safe, Everything Changes 44 min · 28 Sep 2026 · Your World Within Podcast by Eddie Pinero

Azerbaijan GP Driver Ratings 1h 9m · 28 Sep 2026 · P1 with Matt and Tommy

Report any issue

Source

Recorded30 May 2024

Publisheraudioboom.com ↗

Handlerec:11180805

Show notes

In this interview, we welcome the CEO of Novo Holdings, which manages the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. Novo Holdings is part of the Novo Group, which also incorporates Novo Nordisk and Novonesis (who combined are responsible for much of Novo Holdings’ inflows). Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat serious chronic diseases, built upon their heritage in diabetes. Novonesis, also part of Novo Group, serves 130 markets with enzymatic, microbial and advanced protein solutions. As of year-end 2023, Novo Holdings had total assets under management of €149bn (DKK 1,114 bn). In addition to managing a broad portfolio of equities, bonds & other assets, it also has a substantial allocation into life sciences. In this illuminating discussion, Kasim shares Novo Holding’s asset allocation, their corporate structure, the European regulatory context, their long term mission and the importance of the foundation’s life-saving work. Kasim also covers balancing disbursements to the Novo Nordisk Foundation & re-investment in the fund, some criteria for working with external managers, their engaged ownership approach (especially in life sciences) and why they’re comfortable as a public firm. He also discusses the challenge of increasing antibiotic resistance, how biology is assisting in the green transition and the breathtaking development of medical research (including the revolutionary role of AI in diagnostics). The Money Maze Podcast is kindly sponsored by Schroders, IFM Investors and the World Gold Council. Sign up to our Newsletter | Follow us on LinkedIn | Watch on YouTube

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related